<DOC>
	<DOC>NCT01721265</DOC>
	<brief_summary>All subjects in this study have previously been in an Idenix HCV study and received study drug for 3 consecutive days. Subjects who had received placebo in a previous Idenix study will not be enrolled in this study. In this study, researchers will try to find answers to these questions: - How much (if any) hepatitis C virus is in your blood after stopping your Idenix study drug? - Is your hepatitis C virus possibly resistant to treatment with the Idenix study drug or similar drugs?</brief_summary>
	<brief_title>3-Year Observational Virology Follow-up Study in Subjects Who Participated in Studies of Idenix Anti-HCV, Direct Acting Antivirals</brief_title>
	<detailed_description>The data obtained from this study will be used to further understand the long-term efficacy of Idenix DAAs used to treat HCV infection and to further understand HCV resistance to Idenix DAAs.</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Antiviral Agents</mesh_term>
	<criteria>Read and signed the written informed consent form (ICF) after the nature of the study has been fully explained Have participated in an Idenixsponsored study of an Idenix DAA Received at least 3 consecutive days of DAA treatment in an Idenixsponsored study Agreed to comply with the visit schedule and laboratory tests Treatment with placebo only, in an Idenix sponsored study Antiviral treatment for HCV after participation in an Idenix sponsored study of an Idenix DAA</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>HCV</keyword>
	<keyword>Hepatitis C</keyword>
	<keyword>IDX184</keyword>
	<keyword>IDX719</keyword>
</DOC>